Treatment of Severe Tumoral Calcinosis with Teriparatide in a Dialysis Patient after Total Parathyroidectomy
Author(s) -
HoKwan Sin,
P.C. Wong,
KinYee Lo,
ManWai Lo,
ShukFan Chan,
Kwok-Chi Lo,
Yuk-Yi Wong,
LoYi Ho,
WingTung Kwok,
Kai-Chun Chan,
Andrew K. Wong,
SiuKa Mak
Publication year - 2021
Publication title -
case reports in nephrology
Language(s) - English
Resource type - Journals
eISSN - 2090-6641
pISSN - 2090-665X
DOI - 10.1155/2021/6695906
Subject(s) - medicine , tumoral calcinosis , parathyroidectomy , asymptomatic , teriparatide , surgery , hemodialysis , dialysis , calcinosis , osteoporosis , calcification , parathyroid hormone , bone mineral , calcium
Tumoral calcinosis is a rare but debilitating condition that can affect dialysis patients. Optimal management is largely unknown. We report the clinical course, treatment, and outcome of a peritoneal dialysis (PD) patient who developed tumoral calcinosis refractory to conventional treatment but improved with teriparatide therapy. A 26-year-old lady on PD for 2 years presented to us with tumoral calcinosis involving bilateral hands. Response to surgical excision, parathyroidectomy, and conversion to hemodialysis failed to result in sustained remission, and tumoral calcinosis progressed. After total parathyroidectomy, the patient had transient but partial remission in which her calcinosis deposits remained but were asymptomatic without pain or clinical signs of inflammation. However, she later experienced a relapse with involvement of the left elbow, right shoulder, right hip, and right thigh. Tumoral calcinosis remained uncontrolled resulting in debilitation, likely attributable to poor calcium and phosphate control because of adynamic bone disease after parathyroidectomy despite treatment of superimposed tuberculosis and therapy with sodium thiosulphate and pamidronic acid. Clinical improvement was however evident after the use of teriparatide. Asymptomatic hypocalcemia occurred after teriparatide therapy but resolved after 2 months. In conclusion, teriparatide appears to be useful for treating tumoral calcinosis in the presence of adynamic bone disease. Hypocalcemia can occur in the initial months of therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom